Study # D926XC00001

A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy

Meta

Study Status:

Enrolling

Treatment Agent:

Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab

Description

Short Title: TROPION - BREAST 03

The study will investigate the efficacy and safety of Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab) in participants with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Resources and Links

National Clinical Trial Identified Number: NCT05629585

Information and next steps

Disease:

  • Stage I-III Triple-negative Breast Cancer

Study Phase:

III

Physician Name: